You are viewing a single comment's thread.

view the rest of the comments →

MercurysBall2 ago

Re Moderna : "Canadian government scientist under investigation trained staff at Level 4 lab in China"

"Moderna was founded in 2010 and the name was originally written "ModeRNA".[3] It was based on basic science work by Derrick Rossi at Harvard, whose lab developed a method for modifying mRNA, transfecting into human cells, and dedifferentiating them into stem cells, and then causing them to differentiate into desired cell types.[4] Rossi approached fellow Harvard faculty member Tim Springer who had started a company before, about starting a company and Kenneth R. Chien; they brought in Bob Langer and then all of them met with Noubar Afeyan, the CEO of Flagship Ventures.[4][5] After some further validating experiments, the company was founded.[4] Stéphane Bancel, left his job as CEO of bioMérieux to become CEO in 2011.[4] It operated in stealth mode until December 2012, with a vague website and all employees working under strict confidentiality agreements;[5][6] People thought Moderna was a stem cell company until it emerged from stealth mode in 2012, by which time it had raised $40 million from Flagship Ventures' VentureLabs unit and other private investors.[2][4]

In March 2013, Moderna and AstraZeneca signed a five-year exclusive option agreement to discover, develop and commercialize mRNA therapeutics for the treatment of serious cardiovascular, metabolic and renal diseases as well as selected targets in oncology.[7][8] The agreement included a $240 million upfront payment to Moderna, a payment that is "one of the largest ever initial payments in a pharmaceutical industry licensing deal that does not involve a drug already being tested in clinical trials."[7]

In October 2013, the Defense Advanced Research Projects Agency (DARPA) awarded Moderna a grant worth up to $24.6 million to research and develop its mRNA drug technology to fight infectious diseases and biological weapons."

Dr Tim Alefantis is working on this type of vaccine : Sanofi Pasteur: fighting influenza by improving today and innovating for tomorrow by Timothy Alefantis,

Mario Barro,

Iris De Bruijn,

Philippe-Alexandre Gilbert,

Ana Goncalvez,

Rosalind Hollingsworth,

Harold Kleanthous,

Armaghan Naik,

Konstantin Pugachev,

Deborah Rudin,

John Shiver,

Saranya Sridhar,

William Warren &

Jianxin Zhang

Equally, messenger RNA (mRNA)-based technologies hold promise, given its ability to preserve sequence fidelity and deliver a multivalent vaccine formulation that could address the need to cover co-circulating virus drift variants.